PT -期刊文章盟-拉斐尔施耐德盟Koroboshka Brand-Arzamendi AU -盖Lim盟丽莎Eunyoung李盟——媚兰Guenette盟Suradech Suthiphosuwan Jiwon哦TI - AU - Aditya Bharatha盟等离子胶质原纤维酸性蛋白水平与不利的影像放射检查隔离措施综合症(p1 - 3.003) - 10.1212 / WNL援助。0000000000202516 DP - 2023年4月25日TA -神经病首页学第六PG - 2386 - 100 IP - 17补充2 4099 - //www.ez-admanager.com/content/100/17_Supplement_2/2386.short 4100 - //www.ez-admanager.com/content/100/17_Supplement_2/2386.full所以Neurology2023 4月25日;100 AB -目的:研究等离子体是否GFAP (pGFAP)水平与成像技术措施,可以用作预后患者血液生物标志物RIS (pwRIS)。背景:放射检查孤立综合征(RIS)描述了人没有以前或现在MS症状特征病变在脑MRI与女士(pwm)。没有明确如何管理pwRIS以证据为基础的指导方针。成像和blood-based生物标志物进行承诺pwRIS潜在工具指导治疗决策。我们曾表明,大多数pwRIS显示高比例的白质病变(wml)展示中央静脉(CVS)和至少一个顺rim病变,慢性的成像生物标志物,活跃的wml女士(PRL)。胶质原纤维酸性蛋白(GFAP)是一个潜在的血液生物标志物的评价但是,女士pwRIS GFAP尚未研究,特别是与CVS和以“。设计/方法:32 pwRIS接受3 t大脑和颈部脊髓磁共振成像和测量水平pGFAP HD-1 Simoa平台(Quanterix)。斯皮尔曼相关系数是用来评估的相关性。结果:pGFAP水平将积极与黑洞的数量,CVS + wml,以“(术中;0.05使用斯皮尔曼相关系数)。结论:本试验研究是第一个证明pGFAP水平正相关的数量:黑洞,CVS + wml,是否在pwRIS。 Given the established relationships between black holes, PRLs and MS disease progression, pwRIS with high pGFAP levels may be at increased risk of developing clinical MS and disability over time. Prospective validation is underway to confirm the prognostic value of GFAP in pwRIS.Disclosure: Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Mrs. Brand-Arzamendi has nothing to disclose. Timothy R. Lim has nothing to disclose. Lisa Eunyoung Lee has nothing to disclose. Melanie Guenette has nothing to disclose. Dr. Suthiphosuwan has nothing to disclose. Aditya Bharatha has nothing to disclose. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from EMD-Serono. The institution of Dr. Oh has received research support from Biogen-Idec.